Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Inclusion Criteria

• •Pathologically confirmed Hodgkin Lymphoma according World Health Organization (WHO) classification.
• •Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).
• •Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted.
• •Patient is willing and able to adhere to the study visit schedule and other protocol requirements.
• •Meet the following lab criteria: Absolute Neutrophil Count (ANC) ≥ 1,5 x 10\^9/L (≥ 1 x 10\^9/L if bone marrow (BM) involvement by lymphoma); Platelet ≥ 75 x 10\^9/L (≥ 50 x 10\^9/L if BM involvement by lymphoma); Hemoglobin ≥ 8 g/dL.
• •Anticipated life expectancy at least 3 months.